Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06814119 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT06814119 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 34 participants.
The verdict
NCT06814119, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens to calderasib levels in a person's body over time. Researchers will measure what happens to calderasib levels in the body when it is given to people with moderate or severe renal impairment (RI) (meaning the kidneys do not work properly) as compared to people who are in good health. Researchers also want to learn about the safety of calderasib when it is given to people with RI and if people with RI can tolerate it.
Interventions
- DRUG Calderasib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2026-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06814119
The ClinicalTrials.gov registry entry for NCT06814119 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Calderasib is the first listed.
NCT06814119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06814119 about?
NCT06814119 is a clinical study titled "A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)". The goal of this study is to learn what happens to calderasib levels in a person's body over time. Researchers will measure what happens to calderasib levels in the body when it is given to people with moderate or severe renal impairment (RI) (meaning the kidneys do not work properly) as compared to...
What is the current status of trial NCT06814119?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2025-04-07. Estimated completion is 2026-02-06.
What interventions are being tested in trial NCT06814119?
The interventions under investigation include: Calderasib (DRUG).
Who is sponsoring clinical trial NCT06814119?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.